Evidence map›Paper›PMID 32259688›Full record

ArticleRespiratory physiology & neurobiology2020

P2X3 receptor antagonism reduces the occurrence of apnoeas in newborn rats.

Pedro Lourenço Katayama, Ana Paula Abdala, Ian Charles, Wioletta Pijacka, Helio Cesar Salgado, Joel Gever, Anthony P Ford, Julian F R Paton

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory physiology & neurobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Gefapixant as a P2X3 receptor antagonist treatment for obstructive sleep apnea: a randomized controlled trial.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024
    Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pedro Lourenço KatayamaBristol CardioNomics Group, School of Physiology, Pharmacology and Neuroscience, Faculty of Biomedical Sciences, University of Bristol, Bristol, BS8 1TD, England, UK; Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Ana Paula AbdalaBristol CardioNomics Group, School of Physiology, Pharmacology and Neuroscience, Faculty of Biomedical Sciences, University of Bristol, Bristol, BS8 1TD, England, UK.
Ian CharlesBristol CardioNomics Group, School of Physiology, Pharmacology and Neuroscience, Faculty of Biomedical Sciences, University of Bristol, Bristol, BS8 1TD, England, UK.
Wioletta PijackaBristol CardioNomics Group, School of Physiology, Pharmacology and Neuroscience, Faculty of Biomedical Sciences, University of Bristol, Bristol, BS8 1TD, England, UK; Department of Cardiovascular, Renal and Metabolism, MedImmune Ltd, Granta Park, Cambridge, UK.
Helio Cesar SalgadoDepartment of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Joel GeverAfferent Pharmaceuticals, San Mateo, CA, USA.
Anthony P FordAfferent Pharmaceuticals, San Mateo, CA, USA.
Julian F R PatonBristol CardioNomics Group, School of Physiology, Pharmacology and Neuroscience, Faculty of Biomedical Sciences, University of Bristol, Bristol, BS8 1TD, England, UK; Department of Physiology, Faculty of Medical and Health Sciences, University of Auckland, Park Road, Grafton, Auckland, 1142, New Zealand. Electronic address: J.Paton@Auckland.ac.nz.

Funding

CRCNS: Modeling the respiratory-sympathetic coupling in neurogenic hypertensionR01AT008632 · NCCIH · INDIANA UNIVERSITY INDIANAPOLIS · PI MOLKOV, YAROSLAV · 2015 to 2019
$1.4M
NCCIH NIH HHS R01 AT008632
6 · The paper itself

Abstract

Hyperreflexia of the peripheral chemoreceptors is a potential contributor of apnoeas of prematurity (AoP). Recently, it was shown that elevated P2X3 receptor expression was associated with elevated carotid body afferent sensitivity. Therefore, we tested whether P2X3 receptor antagonism would reduce AoP known to occur in newborn rats. Unrestrained whole-body plethysmography was used to record breathing and from this the frequency of apnoeas at baseline and following administration of either a P2X3 receptor antagonist - AF-454 (5 mg/kg or 10 mg/kg s.c.) or vehicle was derived. In a separate group, we tested the effects of AF-454 (10 mg/kg) on the hypoxic ventilatory response (10 % FiO

Indexed as

AnimalsAnimals, NewbornApneaCarotid BodyHypoxiaMalePlethysmography, Whole BodyPurinergic P2X Receptor AntagonistsRatsRats, WistarReceptors, Purinergic P2X3Purinergic P2X Receptor AntagonistsReceptors, Purinergic P2X3Apnoea of prematurityCarotid bodyNeonatesP2X3 receptors

Identifiers

PMID32259688
PMCPMC8208833

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.